An Open-label-Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22 Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-

Protocol No

CARGO-CRG-022-101-LBCL

Phase

II

Summary

To test the safety, tolerability, and efficacy (how well it works) of an investigational cancer treatment called CRG-022 a CD22-directed CAR T-Cell Therapy

Description

A Phase 2 Study of CRG-022 in Patients with R/R B Cell Lymphoma after CD19-Directed Car-T Therapy

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

An Open-label-Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22 Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy